| Literature DB >> 1432439 |
P J Kling1, J A Widness, E N Guillery, P Veng-Pedersen, C Peters, P A DeAlarcon.
Abstract
We treated an infant with anemia and chronic renal failure with recombinant human erythropoietin (300 to 750 U/kg subcutaneously per week) and iron (6 mg/kg enterally) from 1 to 4 months of age. A suboptimal pharmacodynamic response was seen at the lower dose. This may have been due to developmental erythropoietin pharmacokinetic differences, that is, relatively greater neonatal plasma clearance and steady-state volume of distribution compared with those in adults.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1432439 DOI： 10.1016/s0022-3476(05)81923-7
Source DB: PubMed Journal: J Pediatr ISSN： 0022-3476 Impact factor: 4.406